Prophylaxis of graft rejection
Conditions
Interventions
Group 1: Tacrolimus HEXAL®/Crilomus® is used following the instructions in Ch. 4.2 of the summary of product characteristics. The study documents routinely collected clinical data and laboratory value
Sponsors
Hexal AG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - male and female patients >=18 - written informed consent - time elapsed after Transplantation >= 6 month - conversion from Prograf® to Tacrolimus HEXAL®/Crilomus® - stable function of graft (S-Creatinine <3,5 mg/dL or <310 µmol/l)
Exclusion criteria
Exclusion criteria: - Patient participating in interventional Trial - known missing compliance of the Patient - acute rejection during last 3 months or antibody medeated therapy against rejection during the last 6 month - known active CMV or BKV replication - active malignancies except basalioma or non-malignant Skin tumours - known contraindication against application of Tacrolimus HEXAL®/Crilomus® according to SMPC - for female patients: pregnancy or breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Extension of the available information of the therapy with Tacrolimus HEXAL®/Crilomus® in routine clinical practice | — |
Secondary
| Measure | Time frame |
|---|---|
| Extension of available information on death, graft rejection, ofter conversion from Prograf to Tacrolimus HEXAL®/Crilomus®; extension of the available information on the tolerability profile of Tacrolimus HEXAL®/Crilomus®: documentation of adverse events | — |
Countries
Germany
Contacts
Public ContactCaroline Schneider
Institut Dr. Schauerte
Outcome results
None listed